Beyond BRCA1 and BRCA2 wild‐type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN
- 11 January 2010
- journal article
- Published by Wiley in Clinical Genetics
- Vol. 77 (2) , 193-196
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS familiesJournal of Medical Genetics, 2008
- Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer familiesFamilial Cancer, 2007
- Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer familiesBreast Cancer Research and Treatment, 2007
- Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma familiesEuropean Journal of Cancer, 2007
- Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast CancerJAMA, 2006
- Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome: Table 1Journal of Medical Genetics, 2004
- Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysisProceedings of the National Academy of Sciences, 2003
- Prediction of pathogenic mutations in patients with early-onset breast cancer by family historyThe Lancet, 2003
- Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sitesBritish Journal of Cancer, 2001
- Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other NeoplasmsScience, 1990